(Namita Pradhan, Intern Journalist) Mumbai; Indian drugmaker with a huge presence on the US market, has connected with legal and policy experts on the US to study the executive order issued by President of US Donald Trump to prioritize the made in America last week.
“In asking the experts of US regarding their think of order”, said pharma officials in awareness to development. As it is necessary to work line by line. As it is an important market and it needed to be taken care of.
On August 6 after the presidential order was issued for the involvement of federal agencies in the procurement of essential medicines, medical countermeasures and critical inputs to buy such items from domestic manufacturers to decrease the countries depends on the foreign manufactures. It has also requested the department and agencies to know the vulnerabilities of the supply chain of the ingredients in the country’s.
China and India together do a supply of more than 70% of finished drugs and active ingredients of pharma to the US. Indian companies do a supply of generic drugs to the USA of 40%.
The Secretary-General of Indian Pharmaceutical Alliance Sudarshan Jain said, “We are still on the process in studying the order”.
The Indian companies have the facilities of manufacturing in more than 15 US states and already have invested $4.5 billion in the country, said by the industry officials.
The industry officials have quoted “ Every country was talking in establishing their own supply chain; which is not practical, so we are saying if it is leading to a diversified chain of supply, then India as an important strategic appliance of US to work together to ensure an affordable supply of API (active pharmaceutical ingredients) and key starting materials to proceed the continuity supply chain”.
Companies like Zydus Cadila and IPCA labs of India have supplied many doses of critical medicines for the Covid-19 treatment which include hydroxychloroquine tablets to the US in past months. It restricts India’s HCQ export to other countries.
Jeff France interim CEO of Association for Accessible Medicines (AAM) a lobby group of the generic drug companies in the US has said, it might not be viable to forward generic production to the US as costs are very low. Without addressing the generic undervaluation and biosimilar medicines at the US with supply plans sustainability and scale.
About Post Author
